Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.

Topics:  kyprolis   velcade   amgen   study   
BING NEWS:
  • 7 Analysts Have This To Say About Amgen
    The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis ... Revenue Growth: Amgen displayed positive results in 3 months. As of 31 December, 2023, the company ...
    04/3/2024 - 12:00 am | View Link
  • Amgen Options Trading: A Deep Dive into Market Sentiment
    The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and ...
    03/28/2024 - 1:03 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News